Circulating tumour DNA-guided adjuvant atezolizumab prolongs disease-free and overall survival in patients with muscle-invasive bladder cancer, a phase 3 trial shows.

Park says patient-specific factors that influence his treatment selection include the presence of liver disease, ...

Based on patterns of recurrence-free survival (RFS) over time in some studies, the researchers determined that 5-year RFS may be a suitable surrogate for measuring cure.

ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.

An innovative new treatment option for bladder cancer, recently approved by the U.S. Food and Drug Administration, has been performed for the first time in Maryland.

The addition of durvalumab to bacillus Calmette-Guérin therapy significantly extended DFS for patients with high-risk non-muscle-invasive bladder cancer, according to results of a randomized phase 3 ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III IMvigor011 study evaluating Tecentriq® (atezolizumab) as an adjuvant treatment ...

Signatera™ changes the paradigm by expanding the adjuvant decision window, with up to 7 tests in the first year post-surgery, enabling effective initiation of treatment only after a positive test ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) reduced the ...

Young cancer, rising health costs, and financial strain are reshaping America's healthcare system as more people under 50 ...